FDA Approves First Generic Versions of Diabetes Drug Farxiga

The $785-per-month price tag on brand-name Farxiga has been a persistent obstacle for patients managing type 2 diabetes, heart failure, or chronic kidney disease. The FDA's approval of the first generic versions of dapagliflozin, the sodium-glucose cotransporter-2 inhibitor behind the Farxiga brand, opens that market to competition for the first time. The drug, made by AstraZeneca, was first approved by the FDA on January 8, 2014, and its indications have since expanded to include heart failure and chronic kidney disease.

The approvals cover multiple generic dapagliflozin products indicated to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors, and to improve glycemic control as an adjunct to diet and exercise. Lupin Limited, headquartered in Mumbai with U.S. operations in Naples, Florida, announced on April 7 that it had received FDA approval for its abbreviated new drug application for dapagliflozin tablets in both 5 mg and 10 mg strengths, certified as bioequivalent to Farxiga for all approved indications. Aurobindo Pharma received FDA approval for the same two strengths the same day.

Dapagliflozin works by blocking roughly 90 percent of glucose reabsorption in the kidneys, with excess glucose then eliminated through urine, reducing blood sugar levels. Heart failure affects approximately 6.5 million adults in the United States, and dapagliflozin's three major indications mean a broad population of patients could see meaningful cost relief as generic competition takes hold.

Generic dapagliflozin has the potential to reduce costs by 80 to 90 percent compared to the brand-name version. Choosing generic dapagliflozin and using a discount program could save patients approximately $460 per month compared to the current brand price. As more generics enter the market, prices tend to decrease further. Lupin said it would begin commercial and distribution planning immediately following the approval, though the company had not disclosed a firm pharmacy launch date. The speed of actual availability at retail pharmacies will depend on each manufacturer's production ramp and distribution logistics.

Farxiga is among the medications selected for direct Medicare price negotiation under the Inflation Reduction Act, with negotiated prices set to take effect in 2026. Generic competition is likely to interact with those negotiated prices in ways that vary considerably by Medicare Part D plan. How pharmacy benefit managers and commercial insurers structure their formularies in the coming months will ultimately determine which option delivers the lower out-of-pocket cost for a given patient.

What to ask your insurer and pharmacist

Generic availability typically improves insurance coverage and reduces prior authorization requirements that have complicated Farxiga access for some patients, but the transition does not happen automatically for everyone. Ask your pharmacist directly whether generic dapagliflozin has been added to the dispensing system and whether your next refill will be substituted automatically. Most states permit pharmacists to substitute an FDA-approved generic without a new prescription unless the prescriber has written "dispense as written" on the original script, so checking in advance of your refill date avoids surprise.

On the insurance side, contact your pharmacy benefit manager to confirm whether generic dapagliflozin has been placed on the formulary's preferred tier and what your updated co-pay will be. Patients who required prior authorization for brand-name Farxiga should specifically ask whether that restriction has been lifted for the generic. Medicare Part D enrollees face an additional layer: plan-level formulary decisions will govern whether generic dapagliflozin or the IRA-negotiated Farxiga price results in lower cost sharing under a specific plan. Plans are not required to list both at preferred rates, and the answer can vary by insurer, making a direct inquiry before the next refill a practical first step.